Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus prophylaxis for prevention of post-ERCP pancreatitis
NL-OMON61281Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Tacrolimus with Placebo (2 arms). Primary endpoint: Occurrence of post-ERCP pancreatitis within 48 hours after ERCP. Started Oct 2026; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NL-OMON61281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61281.